Myriad Genetics Narrows Losses on Strong Q2 Revenue Growth

TL;DR

MYGN is cutting losses and growing revenue, making it a speculative buy for a turnaround.

AI Summary

MYRIAD GENETICS INC reported a net loss of $10.1 million for the three months ended June 30, 2025, a significant improvement from the net loss of $20.3 million in the same period of 2024. Total revenue for the second quarter of 2025 reached $180.5 million, up from $170.2 million in the second quarter of 2024, representing a 6.05% increase. For the six months ended June 30, 2025, the company's net loss was $25.2 million, an improvement from the $40.5 million net loss in the prior year's comparable period. Total revenue for the first half of 2025 was $355.8 million, an increase from $335.1 million in the first half of 2024, marking a 6.18% growth. The company's cash and cash equivalents decreased to $100.3 million as of June 30, 2025, from $115.5 million at December 31, 2024. Operating expenses, including research and development and selling, general, and administrative, remained substantial, contributing to the continued net losses despite revenue growth. The strategic outlook focuses on continued revenue growth, particularly in hereditary cancer testing, which generated $105.2 million in U.S. revenue for Q2 2025.

Why It Matters

This filing indicates MYGN is making progress towards profitability, narrowing its net loss by 50% in Q2 2025 compared to the prior year. For investors, sustained revenue growth of over 6% year-over-year, particularly in its core hereditary cancer testing segment, suggests increasing market adoption and competitive strength against rivals like Invitae. Employees may see increased job security and potential for growth as the company improves its financial health. Customers benefit from continued innovation and access to genetic testing services. The broader market for diagnostic testing could see MYGN emerge as a stronger player, intensifying competition and potentially driving down costs or improving service quality across the industry.

Risk Assessment

Risk Level: medium — The company reported a net loss of $10.1 million for Q2 2025 and $25.2 million for the first half of 2025, indicating continued unprofitability. Cash and cash equivalents decreased by $15.2 million from $115.5 million at December 31, 2024, to $100.3 million at June 30, 2025, which could impact future liquidity if losses persist.

Analyst Insight

Investors should monitor MYGN's next few quarters for continued progress towards profitability and positive cash flow. Consider a small, speculative position if you believe in the long-term growth of genetic testing and the company's ability to execute its turnaround strategy, but be aware of the ongoing net losses and declining cash reserves.

Financial Highlights

revenue

$180.5M

net Income

-$10.1M

cash Position

$100.3M

revenue Growth

+6.05%

Revenue Breakdown

Key Numbers

• $180.5M — Q2 2025 Revenue (Up 6.05% from $170.2M in Q2 2024, indicating revenue growth.)
• -$10.1M — Q2 2025 Net Loss (Improved from -$20.3M in Q2 2024, showing a 50% reduction in net loss.)
• $355.8M — H1 2025 Revenue (Up 6.18% from $335.1M in H1 2024, demonstrating consistent top-line growth.)
• -$25.2M — H1 2025 Net Loss (Improved from -$40.5M in H1 2024, indicating progress towards profitability.)
• $100.3M — Cash and Cash Equivalents (Decreased from $115.5M at Dec 31, 2024, raising concerns about liquidity.)
• 6.05% — Q2 Revenue Growth (Year-over-year increase in total revenue for the second quarter.)
• 6.18% — H1 Revenue Growth (Year-over-year increase in total revenue for the first half.)
• $105.2M — Q2 2025 U.S. Hereditary Cancer Testing Revenue (A significant component of total revenue, highlighting a key business segment.)

Key Players & Entities

• MYRIAD GENETICS INC (company) — filer of the 10-Q
• $10.1 million (dollar_amount) — net loss for Q2 2025
• $20.3 million (dollar_amount) — net loss for Q2 2024
• $180.5 million (dollar_amount) — total revenue for Q2 2025
• $170.2 million (dollar_amount) — total revenue for Q2 2024
• $25.2 million (dollar_amount) — net loss for H1 2025
• $40.5 million (dollar_amount) — net loss for H1 2024
• $355.8 million (dollar_amount) — total revenue for H1 2025
• $335.1 million (dollar_amount) — total revenue for H1 2024
• $100.3 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Industry Context

The in vitro and in vivo diagnostic substances industry is characterized by rapid technological advancements and a strong focus on personalized medicine. Companies like Myriad Genetics operate in a competitive landscape where innovation in genetic testing and diagnostics is crucial for market share. Regulatory oversight and reimbursement policies significantly impact revenue streams and market access.

Regulatory Implications

As a diagnostics company, Myriad Genetics is subject to stringent regulatory oversight from bodies like the FDA and CMS. Changes in reimbursement policies or new regulatory requirements for diagnostic tests could materially impact the company's revenue and profitability. Compliance with evolving healthcare regulations is a continuous operational challenge.

What Investors Should Do

1. Monitor operating expense trends
2. Analyze cash burn rate
3. Track hereditary cancer testing growth

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and operational updates for Myriad Genetics Inc. for the specified quarter.)

Hereditary Cancer Testing

Diagnostic tests that identify inherited gene mutations that increase the risk of developing certain types of cancer. (This is a core business segment for Myriad Genetics, and its revenue performance is a key indicator of the company's success.)

Year-Over-Year Comparison

Myriad Genetics Inc. has demonstrated positive top-line momentum, with Q2 2025 revenue increasing by 6.05% year-over-year to $180.5M, and H1 2025 revenue growing by 6.18% to $355.8M. The company has also made progress in reducing its net loss, with Q2 2025 showing a $10.1M loss compared to $20.3M in the prior year, and H1 2025 reporting a $25.2M loss versus $40.5M. However, cash reserves have declined to $100.3M from $115.5M at the end of 2024, and operating expenses remain a significant factor impacting profitability.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding MYRIAD GENETICS INC (MYGN).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR